Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15839603 | 0.89 | BACE1 (0.49) | BACE1CYP2C8KCNH2 | |
| SCHEMBL15821200 | 0.89 | BACE1 (0.51) | BACE1CYP2C8KCNH2 | |
| SCHEMBL15839653 | 0.89 | BACE1 (0.47) | BACE1CYP2C8KCNH2 | |
| SCHEMBL17260339 | 0.89 | BACE1 (0.47) | BACE1CYP2C8KCNH2 | |
| SCHEMBL15824540 | 0.89 | BACE1 (0.47) | BACE1CYP2C8KCNH2 | |
| SCHEMBL15839714 | 0.87 | BACE1 (0.63) | BACE1CYP2C8KCNH2 | |
| SCHEMBL15839654 | 0.85 | BACE1 (0.57) | BACE1CYP2C8KCNH2 | |
| SCHEMBL15839607 | 0.85 | BACE1 (0.57) | BACE1CYP2C8KCNH2 | |
| SCHEMBL15839709 | 0.85 | BACE1 (0.68) | BACE1CYP2C8KCNH2 | |
| SCHEMBL17260348 | 0.81 | BACE1 (0.69) | BACE1CYP2C8KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935256-B1 | 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2018-01-24 | — | — | EP | disclosed |
| US-9475784-B2 | 4,6-diarylaminothiazines as BACE1 inhibitors and their use for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-25 | — | — | US | disclosed |
| US-9475784-B2 | 4,6-diarylaminothiazines as BACE1 inhibitors and their use for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-25 | — | — | US | disclosed |
| US-20150329506-A1 | 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329506-A1 | 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-19 | — | — | US | disclosed |
| WO-2014098831-A1 | 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329506-A1 | 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BACE1, APP, BACE2 | BACE1 1/4885CYP2C8 1187/4885KCNH2 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.